Coherus BioSciences, Inc. (NASDAQ:CHRS) has been assigned an average recommendation of “Buy” from the eleven research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $38.50.
Several research firms have commented on CHRS. Maxim Group set a $43.00 price objective on shares of Coherus BioSciences and gave the company a “buy” rating in a report on Monday, May 15th. BMO Capital Markets reaffirmed an “outperform” rating and set a $54.00 price objective on shares of Coherus BioSciences in a report on Monday, May 15th. Barclays PLC reiterated an “overweight” rating and set a $46.00 price target on shares of Coherus BioSciences in a research report on Sunday, May 21st. Citigroup Inc. set a $38.00 price target on Coherus BioSciences and gave the company a “buy” rating in a research report on Wednesday, May 17th. Finally, ValuEngine upgraded Coherus BioSciences from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd.
WARNING: This piece of content was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/07/29/coherus-biosciences-inc-nasdaqchrs-receives-average-recommendation-of-buy-from-brokerages-updated-updated-updated.html.
Shares of Coherus BioSciences (NASDAQ:CHRS) traded up 1.52% during trading on Tuesday, hitting $13.40. 247,920 shares of the stock traded hands. Coherus BioSciences has a 1-year low of $12.85 and a 1-year high of $31.98. The stock has a 50 day moving average price of $14.57 and a 200-day moving average price of $20.55. The stock’s market cap is $687.26 million.
Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($1.54) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.54). The business had revenue of $0.16 million for the quarter. Coherus BioSciences had a negative net margin of 76.85% and a negative return on equity of 827.65%. Equities analysts forecast that Coherus BioSciences will post ($5.13) EPS for the current year.
A number of hedge funds have recently modified their holdings of the company. Boston Advisors LLC purchased a new stake in shares of Coherus BioSciences during the second quarter valued at about $244,000. Handelsbanken Fonder AB raised its stake in Coherus BioSciences by 22.2% in the second quarter. Handelsbanken Fonder AB now owns 55,000 shares of the biotechnology company’s stock worth $789,000 after buying an additional 10,000 shares during the period. Goldman Sachs Group Inc. raised its stake in Coherus BioSciences by 239.6% in the first quarter. Goldman Sachs Group Inc. now owns 141,095 shares of the biotechnology company’s stock worth $2,984,000 after buying an additional 99,548 shares during the period. Credit Suisse AG raised its stake in Coherus BioSciences by 15.4% in the first quarter. Credit Suisse AG now owns 164,113 shares of the biotechnology company’s stock worth $3,472,000 after buying an additional 21,958 shares during the period. Finally, Tudor Investment Corp ET AL raised its stake in Coherus BioSciences by 61.3% in the first quarter. Tudor Investment Corp ET AL now owns 23,223 shares of the biotechnology company’s stock worth $491,000 after buying an additional 8,827 shares during the period. 73.36% of the stock is owned by institutional investors and hedge funds.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.